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Abstract
Background: Pharmacological inhibition of endothelial arginase-II has been shown to improve
endothelial nitric oxide synthase (eNOS) function and reduce atherogenesis in animal models. We
investigated whether the endothelial arginase II is involved in inflammatory responses in endothelial
cells.
Methods: Human endothelial cells were isolated from umbilical veins and stimulated with TNFα
(10 ng/ml) for 4 hours. Endothelial expression of the inflammatory molecules i.e. vascular cell
adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin were
assessed by immunoblotting.
Results: The induction of the expression of endothelial VCAM-1, ICAM-1 and E-selectin by TNFα
was concentration-dependently reduced by incubation of the endothelial cells with the arginase
inhibitor L-norvaline. However, inhibition of arginase by another arginase inhibitor S-(2-
boronoethyl)-L-cysteine (BEC) had no effects. To confirm the role of arginase-II (the prominent
isoform expressed in HUVECs) in the inflammatory responses, adenoviral mediated siRNA
silencing of arginase-II knocked down the arginase II protein level, but did not inhibit the up-
regulation of the adhesion molecules. Moreover, the inhibitory effect of L-norvaline was not
reversed by the NOS inhibitor L-NAME and L-norvaline did not interfere with TNFα-induced
activation of NF-κB, JNK, p38mapk, while it inhibited p70s6k (S6K1) activity. Silencing S6K1
prevented up-regulation of E-selectin, but not that of VCAM-1 or ICAM-1 induced by TNFα.
Conclusion: The arginase inhibitor L-norvaline exhibits anti-inflammatory effects independently of
inhibition of arginase in human endothelial cells. The anti-inflammatory properties of L-norvaline
are partially attributable to its ability to inhibit S6K1.
Background
The vessel wall inflammation constitutes a major factor in
atherogenesis [1,2]. The initial step of atherosclerosis is
inflammatory cell invasion into the intima upon the onset
of inflammation. This process is predominantly mediated
by the interaction of complementary cellular adhesion
molecules on the endothelium and the inflammatory
cells. The endothelial adhesion molecules, including vas-
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adhesion molecule-1 (ICAM-1) and E-selectin, are
expressed on the vascular endothelium when the
endothelial cells (ECs) undergo inflammatory activation
in response to cytokines such as TNFα [3]. E-selectin is
involved in the rolling and tethering of leukocytes on the
vascular wall, whereas VCAM-1 and ICAM-1 induce firm
adhesion of inflammatory cells at the vascular surface [3].
Several lines of evidence support a crucial role of endothe-
lial adhesion molecules in the development of atheroscle-
rosis and plaque instability. Expression of VCAM-1,
ICAM-1 and E-selectin has been observed in ECs of
human atherosclerotic lesions [4,5]. Moreover, mice
genetically deficient in any of these endothelial adhesion
molecules have reduced atherosclerotic lesion formation
in atherosclerosis-prone ApoE-/- or LDLR-/- mice [6-10].
The endothelium-derived nitric oxide (NO), an important
vasoprotective factor, is produced from the substrate L-
arginine by endothelial NO synthase (eNOS) [11]. In
addition to the functions in regulation of vascular tone
and inhibition of platelet aggregation [12], NO has also
been shown to inhibit leukocyte adhesion to the endothe-
lium [13,14], which might be partially attributable to the
inhibition of endothelial VCAM-1 and ICAM-1 expression
[15,16]. Recent research work provides accumulating evi-
dence for the involvement of arginase in decreased
endothelial NO production through competition with
eNOS for the substrate L-arginine [17]. There is increasing
number of studies showing that enhanced arginase gene
expression and/or activity contribute to endothelial dys-
function in various cardiovascular disorders including
atherosclerosis [18,19]. Most recently, it was reported that
in vivo pharmacological treatment of ApoE-/- mice with
arginase inhibitors improves endothelium-dependent
relaxations and reduces atherosclerotic plaque lesion for-
mation [19], implicating the potential role of endothelial
arginase in pathogenesis of vascular diseases. It has how-
ever, not been confirmed whether the beneficial effects of
arginase inhibitors are indeed attributable to the inhibi-
tion of arginase, in another word, whether the endothelial
arginase is indeed involved in inflammatory responses. In
the present study, we elucidated the pharmacological
effects of arginase inhibitors on endothelial inflamma-
tions and the role of arginase in endothelial inflammation
was then clarified by small interfering RNA (siRNA)-based
specific knocking down of the enzyme in the cells.
Methods
Materials
Reagents were purchased from the following sources:
recombinant human TNFα was purchased from
Brunschwig (Basel, Switzerland); S-12-bromoethyl-L-cys-
tine-HCl (BEC) was from Calbiochem; L-norvaline and
anti-tubulin monoclonal antibody were from Sigma
(Buchs, Switzerland). Both BEC and L-norvaline are dis-
solved in distilled water and further diluted in culture
medium. Anti-VCAM-1, -ICAM-1 and -E-selectin antibod-
ies were from Santa Cruz (Nunningen, Switzerland); anti-
IκB, -phospho-IκB-S32, -phospho-c-jun-S63, -phospho-
CREB-S133, and -phospho-S6-S235/236 were from Cell
Signaling (Allschwil, Switzerland); rabbit anti-S6K1 was
from Dr. G. Thomas (Genome Research Institute, Univer-
sity of Cincinnati, USA) [20]; Endothelial cell growth sup-
plement (ECGS) pack was from Promocell GmbH
(Allschwil, Switzerland); all of the cell culture medium
and materials were purchased from Gibco BRL (Basel,
Switzerland).
Cultivation of human umbilical vein endothelial cells 
(HUVECs)
Endothelial cells were isolated from human umbilical
veins and cultivated as described [21]. Cells of 1st to 4th
passages were used.
Generation of recombinant adenoviral (rAd) expressing 
short hairpin RNA (shRNA)
Generation of recombinant adenovirus expressing shRNA
targeting human arginase II (ARG II) or p70s6k (S6K1)
[22] driven by the U6 promoter (rAd/U6-ARGIIshRNA or -
S6K1shRNA, respectively) was carried out with the Gateway
Technology (Invitrogen life Technologies). The sequence
below (only the sense strand is shown) was first cloned
into the Gateway pENTR/U6 Vector. A LR recombination
reaction between the entry clone pENTR/U6-ARGIIshRNA
or -S6K1shRNA and a Gateway destination vector pAd/
BLOCK-iT-DEST was then performed to obtain a recom-
binant adenoviral expression clone pAd/U6-ARGIIshRNA or
-S6K1shRNA, respectively. The resultant recombinant virus-
mids were digested with PacI and transfected into E1-
complementing packaging cells (HER911) to generate
recombinant adenoviruses. The primary crude lysates of
the recombinant adenoviruses were prepared as viral
stocks and used to infect HER911 cells to scale up the viral
preparation. The viral titer was determined by plaque
assay. The control recombinant adenoviruses expressing
shRNA targeting LacZ was from Invitrogen life Technolo-
gies. In boldface are the targeting DNA sequences.
Arginase II targeting sequence:
a. CACCGCAGTAGATGTGATTGCTTCGAAAAGCAATCA-
CATCTACTGC;
b. CACCGCATATTGTCTATGACCAACTCGAAAGTTGGT-
CATAGACAATATGC;
c. CACCGCGAGTGCATTCCATCCTGAACGAATTCAG-
GATGGAATGCACTCGC.
S6K1 targeting sequence: CACCGGACATGGCAGGAGT-
GTTTGACGAATCAAACACTCCTGCCATGTCC.Page 2 of 7
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HUVEC were seeded at a density of 2 × 105/6 cm dish in
complete RPMI-1640 supplemented with 5% FCS and
ECGS. Two days later, cells were transduced with the
recombinant adenovirus at titers of 100 MOI and cultured
in complete medium for 3–4 days. The cells were then
serum-starved in 0.2% FCS RPMI-1640 for 24 hours
before treatment and extraction on days 4 of post-trans-
duction (4 d p.t).
Expression of the adhesion molecules VCAM-1, ICAM-1, E-
selectin
Cell lysate preparation, SDS-PAGE, transfer of SDS gels to
an Immobilon-P membrane (Millipore) were performed
as previously described [21]. The resultant membrane was
first incubated with the corresponding primary antibody
at room temperature for 2 – 3 hours with gentle agitation
after blocking with 5% skimmed milk. The blot was then
further incubated with a corresponding anti-mouse (Alexa
fluor 680 conjugated) or anti-rabbit (IRDye 800 conju-
gated) secondary antibodies and the signals were visual-
ized using Odyssey Infrared Imaging System (LI-COR
Biosciences). Quantification of the signals was performed
using the Odyssey Application Software 1.2.
Activation of NF-κB, JNK, p38mapk, and S6K1
Activation of NF-κB, JNK, p38mapk and S6K1 pathways
was assessed by immunoblotting of phospho-IκB-S32/
total IκB, phospho-c-jun-S63, phospho-CREB-S133, and
phospho-S6-S235/236, respectively.
Statistics
Data are given as mean ± SEM (standard error of mean).
In all experiments, n equals the number of individual
experiments. The ANOVA with Bonferroni's post-test was
used for statistical analysis. Differences in mean values
were considered statistically significant at p < 0.05.
Results
L-norvaline inhibits TNFα-induced endothelial 
inflammation
Stimulation of the endothelial cells with TNFα (10 ng/ml)
for 4 hours strongly enhanced the expression of the exam-
ined inflammatory adhesion molecules, i.e. VCAM-1,
ICAM-1, E-selectin as assessed by immunoblotting analy-
sis (Fig. 1, lane 2, n = 5). This effect of TNFα was concen-
tration-dependently prevented by pre-incubation of the
cells with the arginase inhibitor L-norvaline (1 to 40
mmol/L) (Fig. 1, lanes 3–6, n = 5, ***p < 0.001, **p <
0.01, *p < 0.05 vs. TNFα alone).
L-norvaline inhibits endothelial inflammation 
independently of NOS activity
To examine whether the inhibitory effects of L-norvaline
on expression of VCAM-1, ICAM-1, E-selectin are through
increased NOS activity, the endothelial cells were pre-
incubated with L-NAME (0.1 mmol/L) for 1 hour (to
inhibit NOS activity in the cells [18]) before treatment
with L-norvaline (20 mmol/L) followed by stimulation
with TNFα for 4 hours. As shown in Fig. 2, L-NAME did
not reverse the effects of L-norvaline (Fig. 2, compare lane
8 vs. lane 4), although L-NAME significantly augmented
the TNFα-induced effect on the VCAM-1 and ICAM-1
expression (Fig. 2, lane 6 vs. lane 2, n = 5, ***p < 0.001,
**p < 0.01 vs. TNFα alone).
L-norvaline inhibits endothelial inflammation 
independently of arginase
Next we investigated whether the anti-inflammatory
effects of L-norvaline are dependent on arginase activity.
For this purpose, the endothelial cells were either pre-
treated with another arginase inhibitor BEC (Fig. 3) or
transduced with recombinant adenovirus expressing
shRNA targeting arginase-II (Fig. 4), the principle arginase
isoform in HUVECs [18]. Our experiments showed that
BEC at the concentration of 200 μmol/L exerted inhibi-
tory effects on arginase activity (51.9 ± 7.0% inhibition)
which was comparable to that of 20 mmol/L L-norvaline
(52.4 ± 3.9% inhibition, n = 4). However, in contrast to L-
Effect of L-norvaline on TNFα-induced expression of VCAM-1, ICAM-1, and E-s lectinFigure 1
Effect of L-norvaline on TNFα-induced expression of 
VCAM-1, ICAM-1, and E-selectin. (A) Stimulation of 
HUVECs with TNFα (10 ng/ml, 4 hours) increased expres-
sion of VCAM-1, ICAM-1, and E-selectin, which was signifi-
cantly reduced by L-norvaline in a concentration-dependent 
manner. Tubulin in bottom panel served as loading control. 
(B) Quantification of the signals shown in panel A. Represent-
ative data from five independent experiments are reported 
as mean ± SEM. Values are given as percentage relative to 
stimulation with TNFα. *p < 0.05, **p < 0.01, ***p < 0.001 
vs. stimulation with TNFα. o/n = overnight.
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sion of any of the inflammatory molecules (Fig. 3, n = 5).
Similarly, knocking down arginase-II by the two different
shRNAs i.e. shRNA-ARG IIa and c (shRNA-ARG IIb had no
effect and served as a 2nd control in addition to shRNA-
LacZ) also had no effects (Fig. 4, lanes 6 and 8 vs. lanes 5
and 7, n = 5).
L-norvaline inhibits S6K1
Given the above observations, we then tested whether the
anti-inflammatory effects of L-norvaline are attributable
to its ability to interfere with signaling pathway(s)
involved in expression of the inflammatory molecules.
Upon stimulation with TNFα (10 ng/ml, 15 minutes),
NF-κB, JNK, p38mapk and S6K1 pathways were activated,
as monitored by phosphorylation and degradation of IκB
for NF-κB activation, and phosphorylation of the sub-
strate of JNK, p38mapk and S6K1: c-jun, CREB and S6,
respectively (Fig. 5, lane 2). Pre-treatment of the cells with
L-norvaline (20 mmol/L) did not significantly affect the
activation of NF-κB, JNK or p38mapk, but remarkably
inhibited S6K1 activation (Fig. 5, lane 3).
Role of S6K1 in up-regulation of VCAM-1, ICAM-1, and E-
selectin
The role of S6K1 in up-regulation of VCAM-1, ICAM-1,
and E-selectin was then further investigated by recom-
binant adenovirus-mediated RNA interference (RNAi). In
parallel to the abrogated expression of S6K1 (Fig. 6A,
panel a), cells transduced with the rAd-shRNA against
S6K1 exhibited significantly decreased kinase activity
upon stimulation with TNFα (10 ng/ml, 4 hours), as
measured by phosphorylation of its substrate S6 at
serine235/serine236 (Fig. 6A, panel b). In the cells trans-
duced with control viral vector expressing LacZ-shRNA,
TNFα (10 ng/ml, 4 hours) induced up-regulation of
VCAM-1, ICAM-1, and E-selectin (Fig. 6A, panels c to e,
lane 2; n = 5, p < 0.001 vs. LacZ alone lane 1), silencing
S6K1 significantly reduced TNFα-induced up-regulation
of E-selectin, but not that of VCAM-1 and ICAM-1 (Fig.
6B, lane 4; n = 5, p < 0.001 vs. LacZ + TNFα, lane 2).
Discussion
Emerging evidence suggests that increased endothelial
arginase activity decreases L-arginine availability for
eNOS to produce NO under various pathological condi-
L-norvaline-mediated inhibition of VCAM-1, ICAM-1, and E-selectin: indep ndence of NOS activityFigu e 2
L-norvaline-mediated inhibition of VCAM-1, ICAM-1, 
and E-selectin: independence of NOS activity. (A) The 
effects of L-norvaline on TNFα-induced expression of 
VCAM-1, ICAM-1, and E-selectin could not be reversed by 
the NOS inhibitor L-NAME (100 μmol/L). Tubulin in bottom 
panel served as loading control. Shown are representative 
blots from five independent experiments. (B) Quantification 
of the signals shown in panel A. Values are given as percent-
age relative to stimulation with TNFα in the absence of L-
NAME. **p < 0.01, ***p < 0.001 vs. stimulation with TNFα in 
the absence of L-NAME.
VCAM-1
ICAM-1
E-selectin
tubulin
1 2 3 4 5 6 7 8
TNF (10 ng/ml, 4 hrs)
L-NAME (0.1 mmol)
Norvaline (20 mmol/L, o/n)++
+ + + +
+
+ +
+ + +
A.
B.
V
C
A
M
-1
 /
 t
u
b
u
li
n
(%
) 
120
0
30
60
90
150
***
IC
A
M
-1
 /
 t
u
b
u
li
n
(%
) 
120
0
30
60
90
150 **
E
-s
el
e
ct
in
/ 
tu
b
u
li
n
(%
) 
80
0
20
40
60
120
100
++
+ + + +
+
+ +
+ + +
Role of the arginase inhibitor BEC on TNFα-induced expres-si n of VCAM-1, ICAM-1, and -selectinFigure 3
Role of the arginase inhibitor BEC on TNFα-induced 
expression of VCAM-1, ICAM-1, and E-selectin. Stimu-
lation of the cells with TNFα (10 ng/ml, 4 hours) increased 
inflammatory response which was not affected by the argin-
ase inhibitor BEC (200 μmol/L, o/n). Shown are representa-
tive blots from five independent experiments.
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previously shown to improve endothelial NO release via
inhibition of arginase [18]. Treatment of ApoE-/- mice
with arginase inhibitors has been reported to improve
endothelial function and reduce plaque formation [19]. It
is however, not clear whether arginase is indeed involved
in vascular inflammation responses, a crucial mechanism
in atherogenesis. The present study further investigated
whether arginase is involved in the modulation of
endothelial inflammatory responses and whether this is
dependent on NOS activity in endothelial cells. In cul-
tured human endothelial cells, we demonstrate that the
arginase inhibitor L-norvaline exerts anti-inflammatory
effect at the same concentration ranges which exhibit argi-
nase inhibitory activity [18]. It inhibited endothelial
expression of VCAM-1, ICAM-1, E-selectin stimulated by
TNFα. Although inhibition of NOS activity in the
endothelial cells with L-NAME [18] could significantly
augment TNFα-induced expression of VCAM-1 and
ICAM-1, it was unable to reverse the anti-inflammatory
effects of L-norvaline. The results implicate that basal level
of NO exerts a weak but significant anti-inflammatory
effects, which is consistent with the previous findings
[15,16]. The results with L-NAME suggest that L-norvaline
inhibits endothelial inflammation via a mechanism(s)
independently of NO production and/or arginase. To fur-
ther confirm the role of arginase-II, the prominent iso-
form expressed in HUVECs [18] in the inflammatory
responses, another arginase inhibitor BEC and adenoviral
mediated siRNA silencing of arginase-II were employed.
Indeed, pharmacological inhibition of arginase activity
with BEC at the concentration (200 μmol/L) exerts similar
inhibition of arginase activity (51.9 ± 7.0% inhibition) as
20 mmol/L L-norvaline (52.4 ± 3.9% inhibition); how-
ever, it did not show any effects on TNFα-induced expres-
sion of the adhesion molecules. Moreover, efficient
knocking down of arginase-II with two different targeting
sequences (shRNA-ARGIIa and -ARGIIc) did not affect
endothelial expression of the inflammatory molecules
stimulated by TNFα either. Both pharmacological and
specific siRNA silencing approaches therefore reinforce
our conclusion that L-norvaline exerts anti-inflammatory
effects in endothelial cells independently of arginase and
NOS activity.
Role of arginase II silencing on TNFα-induced expression of VCAM-1, ICAM-1, and E-selectinFigure 4
Role of arginase II silencing on TNFα-induced expres-
sion of VCAM-1, ICAM-1, and E-selectin. HUVECs 
were transduced with recombinant adenovirus expressing 
shRNA against LacZ as control (lanes 1 and 5) or arginase II 
(lanes 2–4 and 6 – 8). On day 4 of post transduction, cells 
were serum-starved for 20 h followed by stimulation with 
TNFα (10 ng/ml, 4 hours) and extracted. The knocking down 
effects of various shRNA targeting sequences were assessed 
by immunoblotting as shown in panel A. Panel B shows the 
effects on expression of VCAM-1, ICAM-1, and E-selectin. 
Shown are representative blots from five independent exper-
iments.
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Effects of L-norvaline on TNFα-induced activation of various signaling pathwaysFigure 5
Effects of L-norvaline on TNFα-induced activation of 
various signaling pathways. After pre-treatment of the 
cells with L-norvaline (Nor. 20 mmol/L), the cells were stim-
ulated with TNFα (10 ng/ml, 15 min) as indicated. The 
extracts were subjected to immunoblotting to examine the 
activation of NF-κB by monitoring degradation and phospho-
rylation of IκB. The activation of JNK, p38mapk and S6K1 
pathways were assessed by monitoring phosphorylation of 
their substrate c-jun, CREB and S6, respectively. Shown are 
representative blots from four independent experiments.
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S6K1 in up-regulation of E-selectin by TNFα. In an effort
to analyse the possible underlying mechanisms of L-nor-
valine-mediated inhibition of endothelial inflammatory
responses, we investigated whether the anti-inflammatory
effects of L-norvaline are attributable to its ability to inter-
fere with signaling pathway(s) that could regulate the
expression of adhesion molecules. Various signalling
pathways such as NF-κB, JNK, p38mapk have been shown
to be involved in the up-regulation of VCAM-1, ICAM-1,
E-selectin [23-26]. These mechanisms were however, not
affected by L-norvaline, demonstrating that the com-
pound inhibits endothelial inflammation independently
of the signalling mechanisms. Interestingly, we found that
TNFα-induced S6K1 activation was strongly inhibited by
L-norvaline, indicating that the compound may inhibit
endothelial inflammation via inhibition of S6K1. To con-
firm this hypothesis, we took the siRNA approach to
knock-down the expression and activity of S6K1. Remark-
ably, silencing experiments revealed that suppressing
S6K1 expression and the enzymatic activity inhibited the
expression of E-selectin, but not that of VCAM-1 or ICAM-
1 in response to TNFα. The results demonstrate that the
anti-inflammatory properties of L-norvaline are partially
attributable to its ability to inhibit S6K1. This is the first
study showing that S6K1 plays an important role in the
expression of endothelial inflammatory molecule E-selec-
tin. The mechanisms that are involved in L-norvaline-
mediated inhibition of endothelial VCAM-1 and ICAM-1
expression remain to be investigated in the future study.
Conclusion
In summary, our results demonstrate that the arginase
inhibitor L-norvaline exhibits anti-inflammatory proper-
ties independently of its effect on inhibition of arginase
activity and increased NO production. The anti-inflam-
matory effects are partially attributable to its ability to
inhibit S6K1. This effect of L-norvaline has to be taken
into account, when the drug is used to study functions of
arginase or NO production in biological systems. The
results of our study also implicate that L-norvaline or its
derivatives may be useful drugs to treat inflammatory
responses in cardiovascular system and to prevent cardio-
vascular diseases.
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Effects of silencing S6K1 on expression of VCAM-1, ICAM-1, and E-selectinFigure 6
Effects of silencing S6K1 on expression of VCAM-1, 
ICAM-1, and E-selectin. HUVECs were transduced with 
recombinant adenovirus expressing shRNA against LacZ as 
control (lanes 1 and 2) or S6K1 (lanes 3 and 4). On day 4 of 
post transduction, cells were serum-starved for 20 h fol-
lowed by stimulation with TNFα (10 ng/ml) for 4 hours and 
extracted. (A) The knocking-down effects of shRNA target-
ing S6K1 were assessed by immunoblotting for the expres-
sion of S6K1 (panel a) and for phosphorylation of its 
substrate S6 (panel b). Panels c to e reveal the effects on 
expression of VCAM-1, ICAM-1, and E-selectin. Shown are 
representative blots from five independent experiments. (B) 
Quantification of the signals in (A) (panels c – e). All blots 
were normalized to tubulin expression. Representative data 
from five independent experiments are reported as mean ± 
SEM. Values are given as percentage relative to stimulation 
with TNFα in the control LacZ-shRNA-transduced cells. 
***p < 0.001 vs. stimulation with TNFα in the control LacZ-
shRNA-transduced cells.
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